Journal Article

Substitution of a Nonnucleoside Reverse Transcriptase Inhibitor for a Protease Inhibitor in the Treatment of Patients with Undetectable Plasma Human Immunodeficiency Virus Type 1 RNA

François Raffi, Bénédicte Bonnet, Virginie Ferré, Jean-Luc Esnault, Philippe Perré, Véronique Reliquet, Sophie Leautez, Christine Bouillant, Odile Vergnoux and Pierre Weinbreck

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 31, issue 5, pages 1274-1278
Published in print November 2000 | ISSN: 1058-4838
Published online November 2000 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/317424
Substitution of a Nonnucleoside Reverse Transcriptase Inhibitor for a Protease Inhibitor in the Treatment of Patients with Undetectable Plasma Human Immunodeficiency Virus Type 1 RNA

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Seventy-three patients infected with human immunodeficiency virus type 1 (HIV-1) were enrolled in a prospective observational study to investigate the efficacy and tolerance of substituting a nonnucleoside reverse transcriptase inhibitor (NNRTI) for a protease inhibitor (PI) in patients whose plasma viral load (pVL) was controlled by a PI regimen. After a median follow-up of 52 weeks, 63 patients (86.3%) had undetectable pVLs. The incidence of virological breakthrough at 12 months of follow-up was 6.5% (95% confidence interval [CI], 1–20) among patients who had been antiretroviral naive before receiving HAART and 19.2% (95% CI, 6–34) among patients who had been treated with antiretroviral drugs before receiving the PI regimen (P = .10).

Journal Article.  3266 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.